FERMT1 Antikörper (AA 643-660)

Produktnummer ABIN636303

Dieser Anti-FERMT1 Antikörper ist ein Kaninchen Polyklonal Antikörper zur Detektion von FERMT1 in WB. Geeignet für Human.

Kurzübersicht für FERMT1 Antikörper (AA 643-660) (ABIN636303)

Target: FERMT1 (Fermitin Family Member 1 (FERMT1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser FERMT1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-FERMT1 Antikörper

Bindungsspezifität: AA 643-660

Kreuzreaktivität: Rind (Kuh), Hund, Maus, Non Human Primates, Ratte (Rattus), Xenopus laevis

Kreuzreaktivität (Details): This antibodys immunogen shares 100 % sequence identity with the bovine, canine, Mouse, non-human primates, rat, and xenopus homologs

Aufreinigung: Affinity purified

Immunogen: URP1 antibody was raised in rabbit using AA 643-660 (VHEYIGGYIFLSTRSKDQ) of the 77 kDa human URP1 protein as the immunogen.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:1,000
Optimal conditions should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handhabung: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Details zu FERMT1

Target: FERMT1 (Fermitin Family Member 1 (FERMT1))

Andere Bezeichnung: URP1

Hintergrund: UNC-112 related protein (URP1) was identified following a massive genome-wide transcriptional profiling of lung and colon carcinomas. Named for its strong sequence homology to C. Elegans UNC-112, URP1 was found to be significantly differentially regulated, being over-expressed in 70% of the colon carcinomas and 60% of the lung carcinomas tested.